Анемия у больных хронической обструктивной болезнью легких: коморбидность или системное проявление?


https://doi.org/10.18093/0869-0189-2012-0-2-5-11

Полный текст:


Аннотация

Анемия у больных хронической обструктивной болезнью легких: коморбидность или системное проявление?

Об авторе

Л. И. Дворецкий
Первый Московский государственный медицинский университет им. И.М.Сеченова
Россия

д. м. н., проф., зав. кафедрой госпитальной терапии № 2 лечебного факультета

119991, Москва, ул. Трубецкая, 8, стр. 2. Тел.: 8-916-676-45-45.



Список литературы

1. Agusti A.G., Noguera A., Sauleda J. et al. Systemic effects of chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21: 347–360.

2. Huertas А., Palange Р. COPD: a multifactorial systemic disease. Ther. Adv. Respir. Dis. 2011; 5 (3): 217–224.

3. Tsantes A.E., Papadhimitriou S.I., Tassiopoulos S.T. et al. Red cell macrocytosis in hypoxemic patients with chronic obstructive pulmonary disease. Respir. Med. 2004; 98: 1117–1123.

4. Garcнa*Pachуn E., Padilla*Navas I. Red cell macrocytosis in COPD patients without respiratory insufficiency: a brief report. Respir. Med.2007; 101: 349–352.

5. Tsantes A., Tassiopoulos S., Papadhimitriou S.I. et al. Suboptimal erythropoietic response to hypoxemia in idiopathic pulmonary fibrosis. Chest 2003; 124: 548–553.

6. Tsantes A., Bonovas S., Tassiopoulos S. et al. A comparative study of the role of erythropoietin in the pathogenesis of deficient erythropoiesis in idiopathic pulmonary fibrosis as opposed to chronic obstructive pulmonary disease. Med. Sci. Monit. 2005; 11: CR177–CR181.

7. Andreas S., Anker S.D., Scanlon P.D., Somers V.K. Neurohumoral activation as a link to systemic manifestations of chronic lung disease. Chest 2005; 128 (3): 618–625.

8. Vlahakos D., Kosmas E., Dimopoulou I. et al. Association between activation of the reninangiotensin system and secondary erythrocytosis in patients with chronic obstructive pulmonary disease. Am. J. Med. 1999; 106: 158–164.

9. Ishani A., Weinhandl E., Zhao Z. et al. Angiotensin-converting-enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J. Am. Coll. Cardiol. 2005; 45: 391–399.

10. Pham I., Andrivet P., Sediame S. et al. Increased erythropoietin synthesis in patients with COLD or left heart failure is related to alterations in renal haemodynamics. Eur. J. Clin. Invest. 2001; 31: 103–109.

11. Vlahakos D.V., Marathias K.P., Agroyannis B., Madias N.E. Posttransplant erythrocytosis. Kidney Int. 2003; 63: 1187–1194.

12. Calverley P.M., Leggett R.J., McElderry L., Flenley D.C. Cigarette smoking and secondary polycythemia in hypoxic cor pulmonale. Am. Rev. Respir. Dis. 1982; 125: 507–510.

13. Tassiopoulos S., Kontos A., Konstantopoulos K. et al. Erythropoietic response to hypoxaemia in diffuse idiopathic pulmonary fibrosis, as opposed to chronic obstructive pulmonary disease. Respir. Med. 2001; 95: 471–475.

14. John M., Hoernig S., Doehner W. et al. Anemia and inflammation in COPD. Chest 2005; 127: 825–829.

15. John M., Lange A., Hoernig S. et al. Prevalence of anemia in chronic obstructive pulmonary disease: comparison to other chronic diseases. Int. J. Cardiol. 2006; 111: 365–370.

16. Cote C., Zilberberg M.D., Mody S.H. et al. Haemoglobin level and its clinical impact in a cohort of patients with COPD. Eur. Respir. J. 2007; 29: 923–929.

17. Attaran D., Khajedalouee M., Ahmadi F. et al. Anemia in COPD patients and its relation to serum levels of erythropoietin. Tanaffos 2009; 8 (2): 11–16.

18. Fidan A., Tokmak M., Kiral N. et al. Anemia in COPD and related factors. Chest 2010; 138: 457A.

19. Baldwin E.F., Cournand A., Richards D.W. Pulmonary insufficiency. III. A study of 122 cases of chronic pulmonary emphysema. Medicine (Baltimore) 1949; 28: 201–210.

20. Wilson R.H., Borden C., Ebert R.V. Adaptation to anoxia in chronic pulmonary emphysema. Arch. Intern. Med. 1951; 88: 581–585.

21. Oudijk E.J., Lammers J.W., Koenderman L. Systemic inflammation in chronic obstructive pulmonary disease. Eur. Respir. J. Suppl. 2003; 22 (Suppl. 46): 5s–13s.

22. Wouters E.F. Chronic obstructive pulmonary disease. 5: systemic effects of COPD. Thorax 2002; 57: 1067–1070.

23. Gan W.Q., Man S.F., Senthilselvan A., Sin D.D. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59: 574–580.

24. Celli B.R., MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS / ERS position paper. Eur. Respir. J. 2004; 23: 932–946.

25. Barnes P.J., Celli B.R. Systemic manifestations and comorbidities of COPD. Eur. Respir. J. 2009; 33 (5): 1165–1185.

26. Аgusti A.G. Systemic effects of chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2005; 2: 367–370.

27. Wouters E. Local and systemic inflammation in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2005; 2: 26–33.

28. Hurst J.R., Perera W.R., Wilkinson T.M. et al. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2006; 173: 71–78.

29. Weiss G., Goodnough L.T. Anemia of chronic disease. N. Engl. J. Med. 2005; 352: 1011–1023.

30. Portillo K, Belda J., Antуn P., Casan P. High frequency of anemia in COPD patients admitted in a tertiary hospital (Spanish). Rev. Clin. Esp. 2007; 207 (8): 383–387.

31. Portillo Carroz K. Anemia in COPD: should it be taken into consideration? Arch. Bronconeumol. 2007; 43 (7): 392–398.

32. Casaburi R., Bhasin S., Cosentino L. et al. Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2004; 170: 870–878.

33. Tsantes A.E., Tassiopoulos S.T., Papadhimitriou S.I. et al. Theophylline treatment may adversely affect the anoxiainduced erythropoietic response without suppressing erythropoietin production. Eur. J. Clin. Pharmacol. 2003; 59: 379–383.

34. Marathias K.P., Agroyannis B., Mavromoustakos T. et al Hematocrit-lowering effect following inactivation of reninangiotensin system with angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Curr. Top. Med. Chem. 2004; 4: 483–486.

35. Griffing G.T., Melby J.C. Enalapril (MK-421) and the white cell count and haematocrit [letter]. Lancet 1982; 1: 1361.

36. Gaston R.S., Julian B.A., Diethelm A.G., Curtis J.J. Effects of enalapril on erythrocytosis after renal transplantation. Ann. Intern. Med. 1991; 115, 954–955.

37. Plata R., Cornejo A., Arratia C. et al. Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: a prospective randomised trial. Lancet 2002; 359: 663–666.

38. Mascitelli L., Francesca Р. Anemia and COPD. Chest 2005; 128 (4): 3084.

39. Krishnan G., Grant B.J., Muti P.C. et al. Association between anemia and quality of life in a population sample of individuals with chronic obstructive pulmonary disease. BMC Pulm. Med. 2006; 6: 23.

40. Similowski T., Agusti A., MacNee W., Schonhofer B. The potential impact of anemia of chronic disease in COPD. Eur. Respir. J. 2006; 27: 390–396.

41. Chambellan A., Chailleux E., Similowski T., the ANTADIR observatory group. Prognostic value of the hematocrit in patients with severe COPD receiving long-term oxygen therapy. Chest 2005; 128: 1201–1208.

42. Celli B.R., Cote C.G., Marin J.M. et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004; 350: 1005–1012.

43. Cappell M.S., Nadler S.C. Increased mortality of acute upper gastrointestinal bleeding in patients with chronic obstructive pulmonary disease. A case controlled, multiyear study of 53 consecutive patients. Dig. Dis. Sci. 1995; 40: 256–262.

44. Upchurch G.R. Jr, Proctor M.C., Henke P.K. et al. Predictors of severe morbidity and death after elective abdominal aortic aneurysmectomy in patients with chronic obstructive pulmonary disease. J. Vasc. Surg. 2003; 37: 594–599.

45. Halpern M.T., Zilberberg M.D., Schmier J.K. et al. Anemia, costs and mortality in chronic obstructive pulmonary disease. Cost Effectiv. Resource Allocat. 2006; 4: 17.

46. Mancini D.M., Katz S.D., Lang C.C. et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003; 107: 294–299.

47. Schonhцfer B., Wenzel M., Geibel M., Kohler D. Blood transfusion and lung function in chronically anemic patients with severe chronic obstructive pulmonary disease. Crit. Care Med. 1998; 26: 1824–1828.

48. Emtner M., Porszasz J., Burns M. et al. Benefits of supplemental oxygen in exercise training in nonhypoxemic chronic obstructive pulmonary disease patients. Am. J. Respir. Crit. Care Med. 2003; 168: 1034–1042.

49. Somfay A., Porszasz J., Lee S.M., Casaburi R. Doseresponse effect of oxygen on hyperinflation and exercise endurance in nonhypoxaemic COPD patients. Eur. Respir. J. 2001; 18: 77–84.

50. Schonhцfer B., Bohrer H., Kohler D. Blood transfusion facilitating difficult weaning from the ventilator. Anaesthesia 1998; 53: 181–184.

51. Schonhofer B., Wenzel M., Geibel M., Kohler D. Blood transfusion and lung function in chronically anemic patients with severe chronic obstructive pulmonary disease. Crit. Care Med. 1998; 26: 1824–1828.


Дополнительные файлы

Для цитирования: Дворецкий Л.И. Анемия у больных хронической обструктивной болезнью легких: коморбидность или системное проявление?  Пульмонология. 2012;(2):5-11. https://doi.org/10.18093/0869-0189-2012-0-2-5-11

For citation: Dvoretsky L.I. Anemia in patients with chronic obstructive pulmonary disease: is it co-morbidity or a systemic manifestation? Russian Pulmonology. 2012;(2):5-11. (In Russ.) https://doi.org/10.18093/0869-0189-2012-0-2-5-11

Просмотров: 379

Обратные ссылки

  • Обратные ссылки не определены.


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)